Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.65 USD | -8.78% | -19.20% | -64.44% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 51.96 | 142.4 | 109.6 | 191.9 | 81.44 | - | - |
Enterprise Value (EV) 1 | 51.96 | 142.4 | 109.6 | 186.1 | -16.26 | 30.44 | -11.16 |
P/E ratio | -8.67 x | -9.25 x | -4.33 x | -3 x | -4.65 x | -3.13 x | -4.33 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 9.92 x |
EV / Revenue | - | - | - | - | - | - | -1.36 x |
EV / EBITDA | - | - | - | -4.13 x | 0.61 x | -0.69 x | 0.17 x |
EV / FCF | - | - | - | -4.66 x | 0.69 x | -0.65 x | 0.19 x |
FCF Yield | - | - | - | -21.5% | 145% | -153% | 523% |
Price to Book | - | - | - | -21.8 x | 1.37 x | 3.56 x | 2.27 x |
Nbr of stocks (in thousands) | 6,892 | 8,101 | 8,164 | 10,262 | 11,171 | - | - |
Reference price 2 | 7.540 | 17.58 | 13.43 | 18.70 | 6.650 | 6.650 | 6.650 |
Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 8.209 |
EBITDA 1 | - | - | - | -45.04 | -26.5 | -44 | -64 |
EBIT 1 | - | -14.54 | -25.51 | -45.04 | -26.32 | -43.94 | -46.65 |
Operating Margin | - | - | - | - | - | - | -568.32% |
Earnings before Tax (EBT) 1 | - | -14.49 | -25.33 | -56.2 | -23.27 | -49.44 | -68.13 |
Net income 1 | -5.462 | -14.49 | -25.33 | -56.2 | -19.25 | -49.42 | -68.11 |
Net margin | - | - | - | - | - | - | -829.66% |
EPS 2 | -0.8700 | -1.900 | -3.100 | -6.230 | -1.430 | -2.122 | -1.537 |
Free Cash Flow 1 | - | - | - | -39.97 | -23.6 | -46.7 | -58.4 |
FCF margin | - | - | - | - | - | - | -711.41% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | - | - | - | -10.44 | -7.81 | -3.9 | -3.9 | -10.9 | - | - |
EBIT 1 | -5.92 | -5.914 | -8.754 | -7.674 | -3.169 | -9.97 | -9.76 | -14.86 | -10.44 | -7.81 | -5.188 | -4.899 | -8.428 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.915 | -5.894 | -8.718 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -1.067 | -5.173 | -4.868 | -8.125 | - | - |
Net income 1 | -5.915 | -5.894 | -8.7 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -1.067 | -5.173 | -4.868 | -8.125 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.7500 | -0.7200 | -1.070 | -0.9300 | -0.3800 | -1.190 | -1.070 | -1.630 | -2.330 | -0.1000 | -0.4350 | -0.2400 | -0.3300 | -0.4800 | -0.6900 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/2/22 | 5/4/22 | 8/8/22 | 11/8/22 | 3/31/23 | 5/10/23 | 8/14/23 | 11/8/23 | 3/29/24 | 5/10/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 5.75 | 97.7 | 51 | 92.6 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -40 | -23.6 | -46.7 | -58.4 |
ROE (net income / shareholders' equity) | - | - | - | - | -47.5% | -62.1% | -87.9% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | -0.8600 | 4.840 | 1.870 | 2.930 |
Cash Flow per Share 2 | - | - | - | -4.430 | -1.200 | -1.590 | -1.740 |
Capex 1 | - | - | - | - | 0.8 | 2 | 2 |
Capex / Sales | - | - | - | - | - | - | 24.36% |
Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.44% | 81.44M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ANVS Stock
- Financials Annovis Bio, Inc.